These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12353182)

  • 1. Extending the boundaries of Herpesvirus infections: advances in therapy. Malta, 12 November 2000. Proceedings of a conference.
    J Infect Dis; 2002 Oct; 186 Suppl 1():S1-137. PubMed ID: 12353182
    [No Abstract]   [Full Text] [Related]  

  • 2. [New medication for herpesvirus infections].
    Vesikari T
    Duodecim; 1995; 111(8):680, 683-4. PubMed ID: 8681827
    [No Abstract]   [Full Text] [Related]  

  • 3. Valacyclovir for the management of herpes viral infections.
    Chakrabarty A; Anderson NJ; Beutner R; Tyring SK
    Skin Therapy Lett; 2005 Feb; 10(1):1-4. PubMed ID: 15776202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Future prospects of valacyclovir in treating and preventing herpesviridae infections in immunosuppressed patients].
    Raffi F
    Presse Med; 1997 Jan; 26 Suppl 1():19-21. PubMed ID: 9082437
    [No Abstract]   [Full Text] [Related]  

  • 5. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster.
    Smiley ML; Murray A; de Miranda P
    Adv Exp Med Biol; 1996; 394():33-9. PubMed ID: 8815698
    [No Abstract]   [Full Text] [Related]  

  • 6. [Valacyclovir].
    Biernat-Sudolska M
    Przegl Lek; 1998; 55(11):596-8. PubMed ID: 10216374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valacyclovir.
    Med Lett Drugs Ther; 1996 Jan; 38(965):3-4. PubMed ID: 8551979
    [No Abstract]   [Full Text] [Related]  

  • 8. Labeling updates to genital herpes drug.
    FDA Consum; 2003; 37(6):3. PubMed ID: 14983803
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug of the month. Valaciclovir (Zelitrex)].
    Piérard GE; Nikkels AF
    Rev Med Liege; 1997 Aug; 52(8):553-5. PubMed ID: 9381007
    [No Abstract]   [Full Text] [Related]  

  • 10. Tomorrow's challenges for herpesvirus management: potential applications of valacyclovir.
    Griffiths PD
    J Infect Dis; 2002 Oct; 186 Suppl 1():S131-7. PubMed ID: 12353198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent erythema multiforme unresponsive to acyclovir prophylaxis and responsive to valacyclovir continuous therapy.
    Kerob D; Assier-Bonnet H; Esnault-Gelly P; Blanc F; Saiag P
    Arch Dermatol; 1998 Jul; 134(7):876-7. PubMed ID: 9681359
    [No Abstract]   [Full Text] [Related]  

  • 12. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine herpesvirus 1).
    Cohen JI; Davenport DS; Stewart JA; Deitchman S; Hilliard JK; Chapman LE;
    Clin Infect Dis; 2002 Nov; 35(10):1191-203. PubMed ID: 12410479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs for non-HIV viral infections.
    Med Lett Drugs Ther; 2002 Feb; 44(1123):9-16. PubMed ID: 11828264
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent developments in herpesvirus therapy.
    Naesens L; De Clercq E
    Herpes; 2001 Mar; 8(1):12-6. PubMed ID: 11867011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-herpesvirus challenges in the transplant recipient.
    Ljungman P
    J Infect Dis; 2002 Oct; 186 Suppl 1():S99-S109. PubMed ID: 12353194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
    Fiddian P; Sabin CA; Griffiths PD
    J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
    Perry CM; Faulds D
    Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
    Tyring SK; Baker D; Snowden W
    J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpesviruses--a rationale for antiviral treatment in multiple sclerosis.
    Bergström T
    Antiviral Res; 1999 Feb; 41(1):1-19. PubMed ID: 10321575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Histolical background of herpesvirus infections and antiviral drugs].
    Shimada K
    Nihon Rinsho; 1989 Feb; 47(2):245-51. PubMed ID: 2542643
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.